News for NeoGenomics, Inc. (NEO.MX)

NeoGenomics, Inc. (NASDAQ: NEO), a leading provider of oncology testing services, today announced the commercial launch of c-MET CDx for NSCLC, its c-MET compa

Guggenheim has begun its coverage of NeoGenomics (NEO) with a Neutral rating, opting not to set a price target. The firm acknowledges the company's success in c

NeoGenomics, Inc. (NEO) has been assigned a Neutral rating by Guggenheim's analyst, Subbu Nambi. This initial rating reflects a balanced outlook for the company

On May 12, 2025, Warren Stone, President and Chief Operating Officer of NeoGenomics Laboratories, a subsidiary of NeoGenomics Inc (NEO), purchased 5,700 shares

On May 7, 2025, Stephen Kanovsky, a Director at NeoGenomics Laboratories, a branch of NeoGenomics Inc (NEO), purchased 4,000 shares of the company. Following th

On May 6, 2025, analyst David Westenberg from Piper Sandler announced a revised price target for NeoGenomics (NEO), a prominent player in the genetics testing s

Market Analysis by covering: Comfort Systems USA Inc, NeoGenomics Inc, Oddity Tech Ltd. Read 's Market Analysis on Investing.com

NeoGenomics (NEO) has seen its price target reduced by Piper Sandler analyst David Westenberg. The target has been adjusted from $18 to $12. Despite this change

On May 1, 2025, renowned financial services firm Morgan Stanley released an updated analyst report regarding NeoGenomics (NEO), maintaining its current rating f

NeoGenomics, Inc. (”œNeoGenomics” or the ”œCompany”) (NASDAQ: NEO), a leading provider of oncology testing services, today announced that it has paid off

NeoGenomics (NEO) has fully repaid its $201.25 million convertible senior notes due May 1, 2025. The company utilized cash on hand to settle the 1.25% n

Morgan Stanley has revised its price target for NeoGenomics (NEO), bringing it down from $17 to $10. Despite maintaining an Equal Weight rating on the stock, th

BTIG has revised its price target for NeoGenomics (NEO), reducing it to $12 from the previous $17. Despite this change, the firm maintains a Buy rating on the s

BofA analyst Michael Ryskin has adjusted his outlook on NeoGenomics (NEO), reducing the price target to $10 from $12 while maintaining a Neutral rating. This re

NeoGenomics (NEO) has seen its price target slashed by TD Cowen from $17 to $12, though the firm maintains its Buy rating on the stock. The decision follows a r

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiat...

Revenue: $168 million for Q1 2025, an 8% increase over the prior year.Adjusted EBITDA: $7.1 million, marking the seventh consecutive quarter of positive adjust

NeoGenomics (NEO) recently experienced a downgrade from Leerink analyst Puneet Souda, who adjusted the stock's rating from Outperform to Market Perform. In conj

NeoGenomics, Inc (NASDAQ:NEO) Q1 2025 Earnings Conference Call April 29, 2025 8:30 AM ETCompany ParticipantsKendra Sweeney - Vice President, Investor...